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Asthma and allergic rhinitis frequently coexist in the same patient. There is a similarity
and variation as well as potential relationship between asthma and allergic rhinitis. There
is an increasing evidence to suggest a major involvement of airway epithelial cells in
the pathogenesis of asthma and allergic rhinitis. The present review describes the
importance of the airway epithelial cell in the development of allergic airway diseases, its
role as the primary airway defense against exposure of the airway and lung to
inﬂammatory stimuli and antigens and as an important player through activation of
epithelial Toll-like receptors (TLRs) to provide an important link between innate immunity
and allergic disease. Additionally, airway epithelial cells can act as inﬂammatory
promoters capable of directing dendritic cells (DCs) towards a T helper 2 (Th2) response,
and as active producers of several inﬂammatory/anti-inﬂammatory mediators. It is
hypothesized that airway epithelial cells may play as both inﬂammatory initiator and
immuno-pathological feedback regulation between allergic rhinitis and asthma via release
of systemic inﬂammatory mediators. Thus, airway epithelial cells may be valuable
therapeutic targets for discovery and development of new drugs and/or new therapeutic
strategies to treat asthma and allergic rhinitis.
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Asthma is a chronic, inﬂammatory condition of the lower
airways characterized by largely reversible airﬂow obstruc-
tion, airway hyper-responsiveness, and episodic respiratory
symptoms.1 Allergic rhinitis (AR) is a disorder of the upper
airways resulting from IgE-mediated inﬂammation of the nose
upon contact of the nasal mucosa with allergens.1 AR is a
common ailment, affecting 10–25% of the world’s population2
and has an impact on asthma as a public health initiative of
the World Health Organization based on the concept of ‘‘one
airway, one disease’’. Asthma and AR frequently coexist in the
same patient and are thought to share common predisposing
genetic factors which interact with environmental inﬂu-
ences,3 increasing in prevalence over recent decades.
The links between the upper and lower airways were
clinically noted and ﬁrst envisaged in the early 1800s4 and then
gradually elucidated and conﬁrmed as the pathogenic unity of
the upper and lower respiratory tract in allergy. The relationship
between asthma and AR is also supported by epidemiological
studies, by histological, physiological, and immunopathological
characteristics, and by the positive effect of various therapies
on asthma symptoms in patients with rhinitis.5
Airway epithelial cells are the ﬁrst line of defense against
exposure of the airway and lung to inﬂammatory stimuli and
antigens, and epithelial activation is one of characteristics
of asthma and AR, signiﬁcantly associated with allergic
sensitization.6 The association between two diseases is
believed to be primarily due to a common allergic trigger.
Thymic stromal lymphopoietin (TSLP) is a cytokine produced
by airway epithelium, orientating dendritic cells (DCs)
towards a T helper 2 (Th2) response and acting as an
essential link between epithelial cell activation and allergic
inﬂammation.7,8 The present review describes current
evidence that airway epithelial cells are involved in the
pathogenesis of asthma and AR, by reviewing the impor-
tance and central role of airway epithelial cells in the
development of diseases. The potential role of nasal
epithelial cells in the pathogenesis of rhinitis is also
explored separately, although the number of works on nasal
epithelial pathophysiology is limited. It should also be kept
in mind that the results from bronchial epithelial studies
cannot be extrapolated into nasal epithelia, even though
there is a similarity between two.Role in viral infections
Upper airway viral infections (URI), caused by different
types of the virus, are associated with the development ofairway inﬂammation. In particular, human rhinovirus (HRV)
infections could increase numbers of neutrophils and
lymphocytes in the upper airways,9 and induce neutrophil
recruitment to the lower airways in subjects with asthma.
Cold, dry air (CDA) can cause symptoms of rhinitis and
obstructive airway responses. Epithelial cell shedding mostly
accompanies with clinical responses to CDA in the nose.10
Although the pathophysiology of these reactions is not fully
understood, it is possible that the respiratory mucosa of
individuals with CDA hypersensitivity cannot compensate for
the loss of water that occurs on exposure to the stimulus,
leading to epithelial damage. In addition to allergen and air
pollutants, the asthmatic airway is particularly susceptible
to respiratory virus infection, which can contribute to
40–80% of asthma exacerbations in both children and adults.
Of particular signiﬁcance is the ﬁnding in asthma that
viruses usually caused only upper respiratory tract symptoms
also cause exacerbations in patients, especially in certain
seasons.11
The mechanisms by which viral infections can enhance
upper and lower airway inﬂammation are not fully deﬁned,
but the growing evidence supports the concept that viral
modulation of epithelial function may initiate the inﬂam-
matory response (Figure 1). Infection of epithelial cells by
HRV has been shown to provoke the generation of a wide
variety of proinﬂammatory chemokines and cytokines,12
including interleukin (IL)-8(CXCL8), ENA-78(CXCL5), IP-
10(CXCL10), RANTES (CCL5), IL-1, IL-6 and IL-11. Once viral
infection of the epithelium initiates a proinﬂammatory
process, subsequent production of other mediators may
further contribute to the inﬂammation of the airway.Role in innate immune responses
The lung is the largest surface in the body contacting with
the outside environment, and presents an estimated area of
100m2 that comes into contact with approximately 10,000 L
of inhaled air each day. The airway epithelium is the direct
interface with inhaled air and others and forms the initial
defense barrier against inhaled exogenous substances.
Epithelial cells play important roles in host defense,
inﬂammation, and regulation of immune responses.13 A role
for epithelial roles in innate immunity has been described by
the fact that lysozyme and other mucosal substances could
prevent the growth of bacteria and other microorganisms
in the lung and airways.13 Airway epithelium is emerging
as a regulator of innate immune responses to a variety
of insults. The maintenance of mucosal barrier function
integrity is another important component of the epithelial
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Figure 1 Viral modulation of epithelial function may initiate the inﬂammatory response. Airway epithelium serves as a structural
and functional barrier against inhaled and deposited particulate antigens. Dendritic cells and airway macrophages collaborate as
sentinels against foreign particulate antigens by building a transepithelial interacting cellular network. Once viral infection of the
epithelium initiates a proinﬂammatory process, subsequent production of other mediators that are not of epithelial origin may
further contribute to the inﬂammatory status of the airway. The direction of the inﬂammatory reaction is mainly from the epithelial
cells to dendritic cells, as indicated by arrows.
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involved in killing or neutralizing microorganisms through
the production of several families of molecules, including
enzymes, permeabilizing peptides, collectins, protease
inhibitors, and others. The production of these substances
is initiated by pathogen-recognition receptors, such as Toll-
like receptors (TLRs).
In order to explore the effects of antigens in TLR
expression and activation, we studied the density of antigen
with a human bronchial epithelial cell line for 24 h, and
found that antigen increased TLR4 expression and nuclear
factor-kappa B (NF-kB) and ErK1/2 activation, and further
increased IL-8 release and chemotactic activity toward
neutrophils. Accumulation of neutrophils within the airways
in response to antigen appeared to increase the expression
of TLR4 and preferentially orients TLR4 activation toward
subsequent activation of ERK and IL-8 production.Role in adaptive immune responses
Epithelial cells act as an initiator, mediator, and regulator in
innate and adaptive immune responses, as well as the
transition from innate immunity to adaptive immunity. DCs
and airway macrophages collaborate as sentinels against
foreign particulate antigens by building a transepithelial
interacting cellular network.14,15 During inﬂammatory and
immune responses,13 epithelial cells express pattern-recognition
receptors to trigger a host defense response, interact with
DC to regulate antigen sensitization, and release cytokines
to recruit effector cells. Epithelial cells also regulate
adaptive immune cells by expression of soluble and cell-surface molecules that alter the function of DCs, T and B
cells in the airways.15Role in allergic reactions
Although asthma is an inﬂammatory disorder of the
conducting airways involving Th2-type T cells, the epithe-
lium also plays an important role in orchestrating the
inﬂammatory response by interacting with multiple environ-
mental factors to produce a chronic wound scenario
involving tissue injury and aberrant repair.14,15 Part of this
is a primary disruption of epithelial tight junctions that
allows inhaled substances to pass more easily into the
airway wall to interact with immune and inﬂammatory cells.
Aberrant communication between the damaged and stressed
epithelia leads to the generation of growth factors that
interact with the underlying mesenchyme to promote airway
remodeling responses and a more chronic and persistent
inﬂammatory phenotype. Disordered epithelial function
with reduced antioxidant defense and impaired capacity
to produce primary interferon-gamma may also account
for asthmatic susceptibility to air pollution and respiratory
virus infection, respectively.11
AR is characterized by an initial sensitization phase where
allergen exposure results in IgE formation as well as
induction of the humoral response, and subsequent clinical
disease after repeated antigen exposure. Mucosal epithelial
cells may play critical roles in initiating and/or maintaining
local inﬂammation.16 It is accepted that mast cells involve
the early phase inﬂammatory response within minutes of
allergen exposure by the release of mediators, but the
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communicate with the antigens without the involvement
of epithelial cells and whether epithelial cells pass the
message or signal to other cells. Cytokine secretion is a
major feature of the inﬂammatory process in AR, playing an
important role in cellular adhesion, e.g. intercellular
adhesion molecule-1, vascular cell adhesion molecule-1,
and E-selectin on the vascular endothelium. It would be
important to understand the role of epithelial cells in
the recruitment of leukocytes from the circulation to the
mucosa.Role in airway hyper-responsiveness (AHR)
AHR is considered to be related to chronic airway inﬂamma-
tion, including leukocyte inﬁltration, hypersecretion of
mucus, bronchial smooth muscle spasm, and airway wall
remodeling, one of the main clinical features in asthma.17
Non-asthmatic subjects with AR can present with AHR when
exposed to an allergen to which they are sensitized.18 It has
been proposed that the nasal mucosa may process allergens
into a form more capable of inducing nasal and bronchial
reactions. AHR often occurs in patients with AR, even if they
have no asthma symptoms, associated with an increased risk
for developing asthma.19 About 40% of patients with AR were
found to have AHR, with a potential to develop asthma over
the subsequent 4–5 years.20 Among patients with exacerba-
tion of asthma symptoms and the onset of seasonal AR, nasal
allergen challenge resulted in an increased nonspeciﬁc
bronchial responsiveness. Segmental bronchial provocation
in patients with AR rather than asthma results in allergic
inﬂammatory changes in the nose.21
Epithelial cell barrier dysfunction has recently been
considered to be an important mechanism in the develop-
ment of AHR. Current theories concerning its pathogenesis,
apart from the classic allergic theory, include the neuro-
genic airway inﬂammation hypothesis and epithelial defect
hypothesis.22 Bronchial epithelial cells play a critical role in
maintenance of homeostasis in the airway microenviron-
ment through a wide range of biological functions includingFigure 2 Mucus overproduction is prominent pathological change
stimuli induce mucin production in airway epithelium via the effect
the inﬂammatory reaction in mainly from stimulus to EGFR, as indianti-oxidative activity, exocrine/endocrine secretion, mu-
cus production, and antigen presentation.23,34 It is reason-
able to hypothesize that disruption of these functional
processes or defects in airway epithelial integrity may be an
initial step leading to AHR. TLR stimulation could induce
AHR, by JNK and NF-kB signaling pathways, supported by the
ﬁnding that LPS and poly-I-C-induced translocation of NF-kB
p65 to the nucleus and up-regulation of kinin B(1) and B(2)
receptor mRNA and TLRs were expressed in the tracheal
smooth muscle.70 It is also possible that hypertrophy
and hyperplasia of goblet cells may also contribute to the
formation of AHR.24Role in mucus overproduction
Mucus overproduction is a prominent pathological change in
the exacerbation of asthma and AR. Epithelial cells are
downstream targets of molecules that activate IL-13R and
epidermal growth factor receptor (EGFR) and are respon-
sible for mucus production in both protective immune
responses and allergic airway inﬂammatory diseases.23
Multiple stimuli induce mucin production in airway epithe-
lium via effects of EGFR activation24 (Figure 2). Autocrine
activation of EGFR in response to stimuli appears to be an
important mechanism of EGFR activation. EGFR expression
and activation induce goblet cell hyperplasia and metaplasia
and increase mucin production, resulting in epithelial
proliferation, differentiation, migration, and wound repair.
On the other hand, IL-4 affects differentiation of epithelial
cells towards a phenotype that releases more IL-8 and
expresses more mucins.
The g-aminobutyric acid (GABA) system, aquaporin (AQPs)
water channels and LPS-induced over-expression of MUC5AC
seem to play a major role in over-production of mucus.
Mucin over-production can be induced via a GABA system in
airway epithelium,25 and IL-13 appears as a critical role in
regulating airway epithelial GABA signaling. GABAergic
blockade could prevent antigen-induced airway goblet cell
hyperplasia and mucus over-production. The AQPs, a family
of homologous water channels expressed in many epithelialin the exacerbation of asthma and allergic rhinitis. Multiple
s of epidermal growth factor (EGFR) activation. The direction of
cated by arrows.
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brane water transport.26 Although LPS-induced over-expression
of MUC5AC in the airway might be the activation of the
TLR-4 pathway and mediated by the release of tumor
necrosis factor (TNF)-a, IL-1b, and IL-8, evidenced by the
fact that the inhibition of TLR-4 expression could prevent
mucus hypersecretion and AHR.70
Role in allergic cascade
Th2-type inﬂammation has a prominent role in epithelial
disorders during asthma and AR.27 TSLP is capable of
directing DCs towards a Th2 response, providing an essential
link between epithelial cell activation and allergic-type
inﬂammation28,29 and between epithelial injury and gen-
eration of an allergic-type inﬂammatory response.30,31 In
addition, TSLP can interact directly with mast cells to
initiate Th2 cytokine production, providing a non-T cell
route to mediate its pro-allergic effects. TSLP interacts with
DCs to upregulate the co-stimulatory molecules OX40, CD40
and CD80 that facilitate polarization of helper T lympho-
cytes to a Th2 phenotype.32,33 Induction of TSLP production
occurs through the activation of epithelial TLRs, an
important link between innate immunity and allergic
disease. It is possible that airway epithelial cells may
contribute to asthma and AR through the activation of
epithelial TLRs.
TLR-involved mediators
The pattern recognition receptors, including TLRs in the
epithelium and on DCs, are important in the origins of
allergy. Their differential activation is associated with the
prevalence of allergic diseases.34–36 The activation of TLRs
in the airways and nose by viral, bacterial, and fungal
ligands has revealed a profound effect in shaping the
subsequent adaptive immune response in favor of Th1,
Th2, or Treg cells. TSLP production can be induced in airway
epithelial cells by ligands that activate TLR2 and TLR3 to
release TSLP protein, and TLR8 and TLR9 to stimulate TLSP
gene transcription through NF-kB activation. Ligands cap-
able of activating these TLRs include bacterial lipoteichoic
acid and peptidoglycans from bacteria (TLR2), single-
stranded (TLR8) and double-stranded (TLR3) viral RNA, and
CpG DNA motifs in both viruses and bacteria (TLR9).37–41 The
proinﬂammatory cytokines e.g. TNFa, IL-1a, IL-4 and IL-13
can also induce TSLP production to drive TSLP-dependent
maturation of blood CD11c+ dendritic cells. TLR activation
can also be initiated by other factors, such as viruses, dusts,
and chemicals.42
Role in allergic inﬂammation
Airway epithelial cells play a critical and important role in
the development of airway inﬂammation,43 involved in the
polarization of allergen-driven Th2 lymphocyte and in the
production of IL-3, IL-4, IL-5, IL-9, granulocyte-macrophage
colony-stimulating factor and IL-13, which are encoded in a
gene cluster on chromosome 5q.31–34 These cytokines drive
the allergic inﬂammatory response through the recruitmentand activation of leukocytes. IL-4, IL-9 and IL-13, in the
presence of MHC-II-restricted allergen presentation by T
cells and CD40 or OX40 co-stimulation, cause an increased
IgE production with subsequent sensitization of mast cells
and basophils through the binding of allergen-speciﬁc IgE to
high afﬁnity receptors (Fc R1).44–49 Cholinergic stimulation
seems to promote a proinﬂammatory response in epithelial
cells by producing chemokines and TSLP. After allergen
challenge and other types of epithelial injury, both CCL17
and CCL22 could drive TH2 chemotaxis by interacting with
the common CCR4 receptor,50 a basis for therapeutic effects
of corticosteroids and calcineurin inhibitors.51–54Role in airway remodeling
Even though the inﬂammatory reaction in AR and asthma is
similar, the nasal remodeling in patients with rhinitis seems
to be far less extensive than the bronchial in asthmatic
patients.59 The cytokine production from smooth muscle
cells might partly explain differences of remodeling be-
tween them, or genes related to embryologic differentiation
might persist between the nose and bronchi or might be re-
expressed in asthma and rhinitis. A better understanding of
nasal and bronchial remodeling might help to identify new
pathways and new therapeutic strategies to reduce long-
term remodeling in asthma. Structural alterations of bronchi
in mild asthma include epithelial fragility and thickening of
its reticular basement membrane.1 The increasing severity
of asthma is accompanied by increases in airway smooth
muscle mass, vascularity, interstitial collagen, and mucus-
secreting glands.60
Airway remodeling is a major contributing factor to the
pathogenesis of asthma, especially the development of
airﬂow obstruction and the progressive decline in lung
function associated with the duration and severity.55 Airway
epithelial cells play an important role in development of
both airway inﬂammation and remodeling in asthma. The
remodeling with epithelial shedding, collagen deposition
basement membrane thickening, smooth muscle hyperplasia
is a distinctive feature of bronchial asthma.
Th2 cytokines not only affect airway inﬂammation and
innate immunity in the lung, but also epithelial differentia-
tion and airway remodeling.56–60 Oxidative stress is capable
of increasing production of Tn and Ln b2 chain by bronchial
epithelial cells, contributing to remodeling in chronic
inﬂammatory airway diseases.60
Remodeling of the airway wall is considered as a direct
result of the inﬂammatory environment present in the
asthmatic airway, but in many cases the epithelium is the
primary target of mechanical forces in the lung due to
the high loads and deformations.61 Mechanical activation of
the epithelium can lead to profound changes in signaling and
gene expression, and alter epithelial release of cytokines,
nucleotides, and growth factors. The mechanical forces
developed during constriction of intact airways could lead to
EGFR signaling in cultured cells.61 These data raise
important questions about the biochemical links between
mechanical transduction and downstream biochemical acti-
vation in airway epithelial cells. Speciﬁc immunotherapy has
been suggested to affect the natural course of allergic
disease and be effective in the treatment of asthma and AR
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possible that epithelial cells are involved in the efﬁcacy as
message carriers.
Epithelial feedback regulation via systemic
inﬂammation
Recent studies have suggested that other pathways may be
involved in asthma.63–70 Epithelial cells in different organs/
tissues have similarities and variations dependent upon the
organ, function, location, and challenge,68 and can commu-
nicate with each other and play a central role in systemic
reactions and multiple organ dysfunction.69 Airway epithe-
lial cells act not only as a defensive line against inﬂamma-
tory stimuli and antigens, but also may be initiators of
secondary inﬂammatory responses and systemic reactions.
It is suggested that ‘‘feedback regulation’’ between the
upper and lower airway takes place at initiation of the
inﬂammatory process,64,65 possibly through a systemic
pathway, or via cytokine release of airway cells, which are
abundantly present throughout the respiratory mucosa.65,66
Possible mechanisms for the inﬂuence of AR on lower
airways include systemic propagation of nasal inﬂammation
to the bronchial mucosa via effects of mediators and
inﬂammatory cells on bone marrow.67
In conclusion, there is a clear indication that epithelial
cells are involved in the pathogenesis of asthma and AR, as
the ﬁrst line of defense facing local and primary challenges.
Airway epithelial cells are important players in the devel-
opment of airway inﬂammation and remodeling, which act
as an inﬂammatory promoter for initiating both local and
systemic inﬂammation. Structural and functional abnormal-
ities of the epithelium can be both primer and promoter of
airway and distant organ dysfucntion. Airway epithelial cells
may be a valuable therapeutic target for discovering and
developing new drugs and/or new therapeutic strategies for
the treatment of allergic diseases.
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